Next Article in Journal
Effect of Folic Acid Treatment for Patients with Traumatic Brain Injury (TBI)-Related Hospital Acquired Pneumonia (HAP): A Retrospective Cohort Study
Previous Article in Journal
Internal Iliac Artery Embolization within EVAR Procedure: Safety, Feasibility, and Outcome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 24
10.3390/jcm11247401
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer

by
Qunli Xiong
†,
Zhiwei Zhang
†,
Yongfeng Xu
and
Qing Zhu
*
Abdominal Oncology Ward, Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2022, 11(24), 7401; https://doi.org/10.3390/jcm11247401
Submission received: 6 November 2022 / Revised: 6 December 2022 / Accepted: 11 December 2022 / Published: 14 December 2022
(This article belongs to the Section Gastroenterology & Hepatopancreatobiliary Medicine)
Versions Notes

Abstract

:
Pancreatic adenosquamous carcinoma (PASC) is a rare pathological subtype of pancreatic cancer (PC), with a worse prognosis than pancreatic ductal adenocarcinoma (PDAC). Due to its rarity, our knowledge of PASC and its biological characteristics are limited. In this review, we provide an overview of the histogenesis, genetic features, diagnosis, treatment, and prognosis of PASC, as well as pancreatic squamous cell carcinoma (PSCC). The information provided here may help to clarify our understanding of PASC and provide useful avenues for further research on this disease.

1. Introduction

Pancreatic cancer (PC) is currently the seventh-leading cause of cancer-related death worldwide [1]. In the United States, PC is expected to become the second-greatest cause of cancer-related death by 2030, trailing behind only lung cancer [2]. Patients with PC are typically not diagnosed until they reach advanced stages of the disease, thereby preventing radical surgery options [3]. Pancreatic adenosquamous carcinoma (PASC) is a rare histological subtype of PC, accounting for 0.5–4% of cases [4,5,6,7,8], while pancreatic squamous cell carcinoma (PSCC) is less prevalent, making up approximately 0.5% of cases [7,9]. Since the first case was reported by Herxheimer in 1907 [10], many additional incidences of PASC and PSCC (collectively called PSC) have been reported [11,12,13,14,15,16,17,18,19]. The median overall survival of patients with PSC is often less than a year, with a five-year survival rate of less than 5% [5,7,20]. Currently, because of the low incidence of PSC, very limited research has been published on this condition. Herein, we present a systematic overview of PSC, including its histogenesis, genetic features, diagnosis, treatment, and prognosis, so as to clarify our understanding of the disease and to facilitate the development of effective treatments for this condition.

2. Histological Ontogeny

Given that squamous cells are not found in normal pancreatic tissue, the origin of squamous components within pancreatic neoplasms is an important area of research. Two widely accepted hypotheses have guided our current understanding of the origin of squamous components in PSC. The first is the squamous metaplasia theory; the second is the differentiation theory [21,22,23]. The first proposes that squamous metaplasia of the pancreatic ductal epithelium cells occurs due to inflammatory stimulation, followed by subsequent transformation into PSC [23,24,25,26,27]. The causal factors of inflammation can be chronic pancreatitis or obstruction of the pancreatic duct by a clump of tumorigenic cells [28]. Some studies have described an association of PSC with pancreatic intraepithelial neoplasia (PanIN) and proposed a model of adenoma-carcinoma progression. Since cases of pancreatic ductal adenocarcinoma (PDAC) are thought to develop through the adenoma-carcinoma pathway, and, based on the assumption that the squamous component originates from the adenocarcinoma, it is feasible that PSC arises as a developmental sequence, that is, from PanIN to PDAC to PSC [29,30]. Furthermore, during the formation of PASC, keratin K8/18-positive glandular cells have been shown to transdifferentiate into p63-, p40-, and keratin K5/14-positive squamous carcinoma cells [31]. This suggests that the origins of squamous carcinoma arise from metaplastic changes to pre-existing adenocarcinoma. More research is needed to clarify the molecular mechanisms behind the cellular differentiation processes that lead to PSC.
The second theory that is thought to explain the origin of squamous components in PSC is the differentiation theory, which proposes that the same progenitor cell is responsible for the squamous carcinoma and adenocarcinoma components of PASC [32]. Immunohistochemical results have shown that CA19-9, ST-439, and keratin are expressed in both squamous cells and adenoma cells of PSC, providing further evidence in support of this theory [22]. Several recent genetic studies that reported distinct patterns of recurrent copy number aberrations (including 3p21.2–11.1 chromosomal deletions) and common mutations (including to the most frequently mutated genes KRAS and TP53) between the two components of PSC further support the differentiation theory [33,34]. Nevertheless, other theories have been proposed that are less well-adopted, including the collision theory, which states that adenocarcinoma and squamous cell carcinoma represent histologically distinct tumors that arise independently from different sites and eventually combine or fuse [6,22,23,35], as well as the ectopic squamous nest theory [36]. Even in the context of our understanding framed by the squamous metaplasia theory and the differentiation theory, our understanding of the histological ontogeny of PSC remains poorly developed.

3. Genetic Features of PASC

In recent years, technological advances have greatly improved our understanding of the pathogenesis of PSC and provided genomic profiles of the disease (Table 1). One study identified mutations at codon 12 in the KRAS2 gene and loss of the p16 protein in all eight cases of PASC examined [37]. In three cases, loss of the p16 protein was found to be caused by a homozygous deletion in exon 2 of the P16/CDKN2a gene. In 2014, Liu et al. screened PASC cases for core nonsense-mediated mRNA decay (NMD) gene mutations and found that most contained somatic acquired mutations in the UPF1 gene [38]. This represents the first gene known to be selectively mutated in PASC. UPF1 encodes an RNA helicase that is critical for NMD in a highly conserved RNA degradation pathway. The specific mutation identified in PASC patients alters UPF1 RNA splicing and interferes with NMD, resulting in upregulated mRNA levels of NMD substrates [38]. This discovery may provide an avenue for diagnosing PASC, and these patients may benefit from treatments targeting NMD.
A whole-exome sequencing (WES) study of 109 pancreatic cancer samples that included 11 PASC cases suggested that the adenosquamous subtype was closely related to an 8q24 amplification (including the MYC gene) and a FLG gene mutation [39]. In 2017, Xu et al. screened 1033 PC cases and identified two cases of PSCC [40]. To verify the genomic characteristics of PSCC, these authors used high throughput sequencing after in-solution hybrid capture in two PSCC, two PASC, and four PDAC formalin-fixed paraffin-embedded (FFPE) tissues. They identified nine genetic mutations in the PSCC samples, including in the C7orf70, DNHD1, KPRP, MDM4, MUC6, OR51Q1, PTPRD, TCF4, and TET2 genes. A further nine genetic mutations were found in PDAC, including in the ABCB1, CSF1R, CYP2C18, FBXW7, ITPA, KIAA0748, SOD2, SULT1A2, and Z5 genes. Interestingly, the mutations identified in the PASC samples overlapped with those in the PSCC and PDAC tissues. This study may provide valuable information for the pathogenesis of PSCC, as well as for the development of targeted drug therapies.
In 2017, Fang et al. performed whole-exome or whole-genome sequencing (WGS) on 34 PDAC and 17 of PASC and found that the most common single-nucleotide variants in PASC were P53, KRAS, and SMAD4 [33]. Furthermore, a 3p deletion was identified as the most common copy number variant, with the suppressor genes FHIT, ROBO1, ROBO2, and WNT5A all contained in the 3p chromosome. These findings led to the speculation that the two components of adenosquamous carcinoma might be derived from the same progenitor cell. In 2020, Ma et al. reported that mutations in the MAP3K1, PDE4DIP, and BCR genes were often found in the germline of PASC patients after performing whole-exon sequencing on 12 pairs of PASC and paracancerous tissues [41]. Germline mutations in USP6 and somatic mutations in KRAS, OBSCN, and HRNR were associated with the malignancy of PASC. In order to distinguish the genomic map of PASC and identify therapeutic targets, Lenkiewicz et al. used DNA-content flow cytometry to detect 15 tumor samples contained in five patient-derived xenografts (PDX) [42]. Whole-exome sequencing, genome-wide copy number variation (CNV), and transposable chromatin sequencing (ATAC-seq) were also used to analyze the tumor segments that were purified and classified from these samples. Multiple somatic genomic impairments targeting PASC genome chromatin modulators were found, superposed on characteristic genomic impairments, including TP53 (87%) and KRAS (73%) mutations, MYC amplification (47%), and deletion of CDKN2A homozygosity (40%). Moreover, ATAC-seq profiles of the three PASC and three PDAC genomes were compared using the flow-sorting PDX model. Chromatin availability genes specific to PASC genomes were identified in all three PASC cases, including the lysine–methyltransferase gene Smyd2 and the pancreatic cancer stem cell regulatory factor gene RORC. In an additional PASC sample, a FGFR1-ERLIN2 fusion related to focus CNV in two genes was identified. Finally, pan FGFR inhibitors showed significant activity against PASC PDX models derived from a FGFR1-ERLIN2 fusion. Together, this research suggests that the epigenomic and genomic profiles of PASC provide a novel strategy for targeting this aggressive subtype of PC.
Table
Table 1. A comparison of the genetic features between PSC and non-PSC cases.
Table 1. A comparison of the genetic features between PSC and non-PSC cases.
ReferenceSample TypeDetection MethodNumber of CasesCharacteristics
Non-PSCPSCNon-PSCPSC
Brody et al. [37]FFPE tissuesPCR amplification and sequencing;NA8NAKRAS2 gene mutations at codon 12 (100%), exon 2 homozygous deletion in the p16/CDKN2a gene (37.5%)
Liu et al. [38]FFPE tissuesNested PCR and sequencing2923NASomatic UPF1 gene mutations (78.3%)
Witkiewicz et al. [39]Frozen tissuesWES9811KRAS, TP53, CDKN2A, SMAD4, BCLAF1, IRF6, FLG, AXIN1, GLI3, and PIK3CA mutations8q24 locus amplification (including MYC gene) and FLG gene mutation
Xu et al. [40]FFPE tissuesIn-solution hybrid capture targeting cancer-related genes and high throughput sequencing24ABCB1, CSF1R, CYP2C18, FBXW7, ITPA, KIAA0748, SOD2, SULT1A2, and ZNF142 mutationsC7orf70, DNHD1, KPRP, MDM4, MUC6, OR51Q1, PTPRD, TCF4, and TET2 mutations
Fang et al. [33]FFPE tissuesWES, WGS3417KRAS, TP53 (65%), and SMAD4 mutations; gains of 3q, 8q (MYC), 12p (KRAS), and chromosome 19; losses of 3p (FHIT), 4p, 6q, 8p, 9p (CDKN2A), 17p (TP53), and 18q (SMAD4)KRAS (100%), TP53 (88%), and SMAD4 mutations; gains of 3q, 8q (MYC), 12p (KRAS), and chromosome 19; losses of 3p (FHIT) (more frequent in 3p26.3–26.1, 3p25.1–21.31, and 3p21.2–11.1), 4p, 6q, 8p, 9p (CDKN2A), 17p (TP53), and 18q (SMAD4)
Ma et al. [41]Frozen tissuesWESNA12NAMAP3K1 (75%), PDE4DIP (58.3%), BCR (58.3%), ALK (50%), USP6 (41.7%), AR (33.3%), HLA-A (33.3%), SPEN (33.3%), KMT2D (25%), NUTM2B (25%), ZFHX3 (25%), and MN1 (25%) germline mutations; TP53 (41.7%), KRAS (25%), HRNR (25%), and OBSCN (25%) somatic mutations
Lenkiewicz et al. [42]Frozen tissue and FFPE tissuesWhole-genome copy-number variant, WES, and ATAC-seqNA15NATP53 (87%) and KRAS (73%) mutations; amplification of MYC (47%); homozygous deletion of CDKN2A (40%); genes with accessible chromatin including SMYD2, RORC, and FGFR1-ERLIN2 fusion
As shown, genomics studies have significantly enhanced our understanding of PSC. The molecular classification and genetic features continue to support clinicians in making accurate, personalized decisions regarding therapeutic options for patients [43]. However, limited genomic profiling has been performed because cases of PSC are rare, compared with PDAC. There is an urgent need for further exploration of the genetic features of PSC.

4. Diagnosis

According to World Health Organization guidelines [44], PASC is defined as containing at least 30% squamous carcinoma components combined with adenocarcinoma. However, this classification is contentious because the proportion of squamous carcinoma in PASC is not correlated with clinical characteristics, and evaluation of the percentage is subjective [4,23,27,45]. On this issue, large-cohort studies will be important to clarify the significance of proportional definitions for clinical definitions of squamous carcinoma components in PASC. In addition to its clinical relevance, examination of cellular and pathological features are of importance for the diagnosis of PSC.

4.1. Clinical Manifestation and Laboratory Examination

Patients with PSC typically present with abdominal symptoms, obstructive jaundice, and weight loss, which is similar to PDAC [46,47,48,49]. Abnormal function of distant organs and tissues frequently occur following metastasis to other sites, such as the liver, lung [49,50], and even several rare metastatic sites, such as bone and skin [51,52,53]. Laboratory analyses of serum tumor markers have shown that most patients display elevated levels of carbohydrate antigen 19-9 and carcinoembryonic antigen [54]. Humoral hypercalcemia of malignancy may also occur in some patients with PSC, which may be related to elevated levels of serum parathyroid hormone-related protein [26,55,56,57,58].

4.2. Imaging Features

Computed tomography (CT) and magnetic resonance imaging of PSC patients usually depict an ill-defined focus in the head of the pancreas, with peripheral ring enhancement and a poorly enhanced central area of extensive central necrosis. Other characteristics of radiography include vessel invasion, tumor thrombus in the portal vein system, peripancreatic tissue invasion, and upstream main pancreatic duct dilatation. These features may provide useful information for diagnosing PSC and predicting disease prognosis [59,60,61,62,63]. A hypermetabolic pancreatic mass with metastatic sites can be detected with positron emission tomography/CT [64,65]. Additionally, PASC tends to show enhanced fludeoxyglucose uptake on both early and delayed phases when compared to PDAC, and the maximum standardized value and mean retention index have the potential to predict malignancy and invasion of PASC [65].

4.3. Pathological Features

The typical pathomorphological features of squamous carcinoma often manifest microscopically as definite intercellular bridges and/or focal keratin peal formation in the tumor cells. However, PSC tends to present with poorly differentiated pathologically. Therefore, utilizing immunochemistry to confirm squamous differentiation in the absence of overt keratinization is often necessary. Immunohistochemistry analysis of PSC frequently reveals positive expression of p63 and cytokeratin 5/6, with some PSC cases being positive for nuclear p53 staining and showing loss of the Dpc4 protein [37]. The proliferative capacity of PSC can be determined using Ki-67 staining within the tumor [66]. Moreover, some patients with PSC may present with poorly differentiated sarcomatous components with positive P40 staining histopathologically, and the sarcomatous component may be related to the biological malignancy of PASC [67]. In general, the percentage of grade III and IV tumors is higher in patients with PSC than in those with other pancreatic tumors, and PSC tends to present with a large size, poor differentiation, and node-positivity, indicating that PSC is more aggressive [5,7].

5. Prognosis and Treatment

Compared to PDAC, patients with PSC tend to suffer a worse survival rate (Table 2). For example, Imaoka et al. reported that the median overall survival of patients with PDAC was 15.7 months, while that of patients with PSC was 8.3.(p = 0.026) [68]. In the study cohort of Boyd et al., the survival of PSC patients tended to be worse than that of PDAC patients even though there was no statistic difference (p = 0.08); there was also no different in the one-year survival rate [5]. Due to the poor prognosis of PSC, finding effective treatments is a top priority [69]. Currently, the treatment of PASC is similar to that of PDAC. Radical surgery remains the only way to cure a tumor, and the same is true for PSC patients in which surgery is the strongest predictor of survival. The median survival and year-survival rate of patients with PSC undergoing surgery, especially those with R0 surgical resection, are improved compared to patients without radical resection [5,70,71,72]. For example, the postoperative median survival of patients with PSC who underwent radical resection could be as high as 12 months [5,73]. However, the prognosis of patients with pancreatectomy for PSC can still be poor [35,74,75,76]. Okabayashi et al. reported a survival of only 6.8 months after surgical resection of PSC [75]. Aside from surgery, patients with PSC can also benefit from other treatment methods, especially chemotherapies [43,73,77,78,79]. A study of 515 cases of PSCC in which 48% of the cohort who received either chemotherapy, radiation therapy, or both, found that PSC patients in stage IV treated with chemotherapy had a better overall survival than those without chemotherapy, while adjuvant chemotherapy did not improve overall survival in localized early stages [80]. Statistical analyses from 38 patients with PASC demonstrated that the improved survival of PASC patients with a tumor size of at least 3 cm and vascular or perineural invasion was related to adjuvant chemoradiation [4]. Furthermore, retrospective analyses of PASC patients suggested that PASC might be responsive to combined treatments, especially with the inclusion of platinum agents [81,82]. A recent case report documented the success of capecitabine therapy lasting 34.6 months in a 51-year-old female with PASC, who had received surgical resection after experiencing tumor recurrence during initial treatment with gemcitabine [83]. This case highlights that early recurrence during adjuvant chemotherapy for PASC may be compatible with a subsequent exceptional response to second-line chemotherapy. Additional studies have shown that neoadjuvant chemotherapies may improve the successful rate of pancreatectomy surgeries, thereby boosting the prognosis of patients with PSC [84,85,86]. Finally, immunotherapy has become a promising treatment option, with immune checkpoint inhibitors providing therapeutic potential when selectively targeting the squamous components of PASC that express PD-L1 [87].
The low incidence of PSC and the lack of understanding around its biological features prohibit the possibility of clinical trials being carried out in patients with PSC. Therefore, current treatment strategies for PSC are based on clinical studies of PDAC. Although surgery, chemotherapy, and other therapies have improved the prognosis of PSC and long-term survival of patients is now possible [89,90], the effectiveness of these treatments needs to be improved. A comprehensive treatment paradigm that includes surgery, chemotherapy, radiotherapy, and other methods is needed to significantly improve the prognosis of patients with PSC [91,92,93,94,95,96,97].

6. Conclusions

Rare subtypes of pancreatic cancer present with unique clinicopathologic characteristics and display a variety of tumor-specific biological features [98,99,100]. The low incidence of PSC has been limiting for our ability to study this disease. In order to gain a more comprehensive understanding, larger-cohort clinical studies and more fundamental research on the mechanisms underlying the genesis and development of PSC are needed. We propose four potential directions for future PSC research. Firstly, we recommend the collection and analysis of large cohorts of adenosquamous carcinomas with long-term survival and in which tumor site is not limited to the pancreas, in order to identify the similarities between these cases. Secondly, the utilization of advanced technologies, such as single-cell sequencing and spatial transcriptomics, will be critical to uncover more genetic features and the histogenesis of PSC and may provide new therapeutic targets. Thirdly, targeted drugs may be developed based on the unique molecular characteristics of PSC and potential targets. Finally, the establishment of systematic databases and standard therapeutic strategies for rare histology subtypes of pancreatic neoplasms (not only limited to PSC) will be essential to aid clinical decision-making and help to provide more accurate prognostic information for patients with PSC.

Author Contributions

Conceptualization, Q.X. and Q.Z.; methodology, Z.Z.; investigation, Q.X. and Z.Z.; resources, Q.Z.; data curation, Q.Z.; writing—original draft preparation, Q.X. and Z.Z.; writing—review and editing, Y.X.; supervision, Q.Z.; funding acquisition, Q.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Sichuan Science and Technology Programme (2019YFS0042) and 1.3.5 Project for Disciplines of Excellence, West China Hospital (ZYJC21042), Sichuan University for Qing Zhu.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We thank our colleagues for the critical reading and constructive criticism of the manuscript.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014, 74, 2913–2921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef]
  4. Voong, K.R.; Davison, J.; Pawlik, T.M.; Uy, M.O.; Hsu, C.C.; Winter, J.; Hruban, R.H.; Laheru, D.; Rudra, S.; Swartz, M.J.; et al. Resected pancreatic adenosquamous carcinoma: Clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum. Pathol. 2010, 41, 113–122. [Google Scholar] [CrossRef] [Green Version]
  5. Boyd, C.A.; Benarroch-Gampel, J.; Sheffield, K.M.; Cooksley, C.D.; Riall, T.S. 415 patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival. J. Surg. Res. 2012, 174, 12–19. [Google Scholar] [CrossRef] [Green Version]
  6. Simone, C.G.; Zuluaga Toro, T.; Chan, E.; Feely, M.M.; Trevino, J.G.; George, T.J. Characteristics and outcomes of adenosquamous carcinoma of the pancreas. Gastrointest. Cancer Res. GCR 2013, 6, 75–79. [Google Scholar] [CrossRef] [Green Version]
  7. Luo, G.; Fan, Z.; Gong, Y.; Jin, K.; Yang, C.; Cheng, H.; Huang, D.; Ni, Q.; Liu, C.; Yu, X. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Pancreas 2019, 48, 817–822. [Google Scholar] [CrossRef]
  8. Regi, P.; Butturini, G.; Malleo, G.; Pedica, F.; D’Onofrio, M.; Bassi, C. Clinicopathological features of adenosquamous pancreatic cancer. Langenbecks Arch. Surg. 2011, 396, 217–222. [Google Scholar] [CrossRef]
  9. Makarova-Rusher, O.V.; Ulahannan, S.; Greten, T.F.; Duffy, A. Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes. Pancreas 2016, 45, 1432–1437. [Google Scholar] [CrossRef] [Green Version]
  10. Herxheimer, G. Über heterologe Cancroide. Beitr. Pthol. Anat. 1907, 41, 348–412. [Google Scholar]
  11. Kim, T.J.; Sia, T.C.; Gilmore, A. Pancreatic adenosquamous carcinoma masquerading as a locally invading splenic abscess. ANZ J. Surg. 2019, 89, E343–E344. [Google Scholar] [CrossRef] [PubMed]
  12. Kurdi, Y.M.; Peck, J.R.; Roth, R.; Conwell, D.L. A Case of Pancreatic Adenosquamous Carcinoma Obstructing the Common Bile and Pancreatic Ducts, Duodenum, and Gastric Outlet. Pancreas 2016, 45, e9–e10. [Google Scholar] [CrossRef] [PubMed]
  13. Makiyama, K.; Takuma, K.; Zea-Iriarte, W.L.; Ikuno, N.; Kawatomi, M.; Mori, N.; Ishino, T.; Yonemitsu, N. Adenosquamous carcinoma of the pancreas. J. Gastroenterol. 1995, 30, 798–802. [Google Scholar] [CrossRef] [PubMed]
  14. Alajlan, B.A.; Bernadt, C.T.; Kushnir, V.M. Primary Squamous Cell Carcinoma of the Pancreas: A Case Report and Literature Review. J. Gastrointest. Cancer 2019, 50, 130–133. [Google Scholar] [CrossRef] [PubMed]
  15. Anagnostopoulos, G.K.; Aithal, G.P.; Ragunath, K.; Kaye, P.; Rowlands, B.J. Squamous cell carcinoma of the pancreas: Report of a case and review of the literature. JOP 2006, 7, 47–50. [Google Scholar]
  16. Chen, K.; Xu, X.W.; Xie, K.; Zhou, Y.C.; Mou, Y.P. Splenomegaly as the first manifestation of pancreatic adenosquamous carcinoma: A case report. Turk. J. Gastroenterol. 2012, 23, 799–803. [Google Scholar] [CrossRef]
  17. Jamali, M.; Serra, S.; Chetty, R. Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. JOP 2007, 8, 330–334. [Google Scholar]
  18. Sydney, G.I.; Ioakim, K.J.; Sergentanis, T.N.; Tsiotos, G.G.; Kyriakidou, V.; Sepsa, A.; Theocharis, S.; Salla, C.; Nikas, I. Dissecting the presence of malignant squamous cells in pancreatic cytopathology: A case series. Diagn. Cytopathol. 2019, 47, 1287–1292. [Google Scholar] [CrossRef]
  19. Inomata, N.; Masuda, A.; Itani, T.; Hayashi, M.; Shimada, Y.; Adachi, K.; Hashimoto, K.; Tanaka, Y.; Tanaka, A.; Kobayashi, T.; et al. An autopsy case of granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma. Clin. J. Gastroenterol. 2020, 13, 448–454. [Google Scholar] [CrossRef]
  20. Komatsu, H.; Egawa, S.; Motoi, F.; Morikawa, T.; Sakata, N.; Naitoh, T.; Katayose, Y.; Ishida, K.; Unno, M. Clinicopathological features and surgical outcomes of adenosquamous carcinoma of the pancreas: A retrospective analysis of patients with resectable stage tumors. Surg. Today 2015, 45, 297–304. [Google Scholar] [CrossRef]
  21. Boecker, W.; Stenman, G.; Loening, T.; Andersson, M.K.; Berg, T.; Lange, A.; Bankfalvi, A.; Samoilova, V.; Tiemann, K.; Buchwalow, I. Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells. Virchows Arch. 2015, 466, 21–36. [Google Scholar] [CrossRef] [PubMed]
  22. Motojima, K.; Tomioka, T.; Kohara, N.; Tsunoda, T.; Kanematsu, T. Immunohistochemical characteristics of adenosquamous carcinoma of the pancreas. J. Surg. Oncol. 1992, 49, 58–62. [Google Scholar] [CrossRef] [PubMed]
  23. Kardon, D.E.; Thompson, L.D.; Przygodzki, R.M.; Heffess, C.S. Adenosquamous carcinoma of the pancreas: A clinicopathologic series of 25 cases. Mod. Pathol. 2001, 14, 443–451. [Google Scholar] [CrossRef] [PubMed]
  24. Terada, T. Adenosquamous Carcinoma and Pure Squamous Cell Carcinoma of the Pancreas: Report of two Cases. Case Rep. Gastroenterol. 2010, 4, 369–373. [Google Scholar] [CrossRef] [PubMed]
  25. Skafida, E.; Grammatoglou, X.; Glava, C.; Zissis, D.; Paschalidis, N.; Katsamagkou, E.; Firfiris, N.; Vasilakaki, T. Adenosquamous carcinoma of the pancreas: A case report. Cases J. 2010, 3, 41. [Google Scholar] [CrossRef] [Green Version]
  26. Trikudanathan, G.; Dasanu, C.A. Adenosquamous carcinoma of the pancreas: A distinct clinicopathologic entity. South Med. J. 2010, 103, 903–910. [Google Scholar] [CrossRef]
  27. Yamaguchi, K.; Enjoji, M. Adenosquamous carcinoma of the pancreas: A clinicopathologic study. J. Surg. Oncol. 1991, 47, 109–116. [Google Scholar] [CrossRef]
  28. Paramythiotis, D.; Kyriakidis, F.; Karlafti, E.; Didangelos, T.; Oikonomou, I.M.; Karakatsanis, A.; Poulios, C.; Chamalidou, E.; Vagionas, A.; Michalopoulos, A. Adenosquamous carcinoma of the pancreas: Two case reports and review of the literature. J. Med. Case Rep. 2022, 16, 395. [Google Scholar] [CrossRef]
  29. de Juan, F.M.; Escribano, M.R.; Lapiedra, C.M.; de Alcantara, F.M.; Soto, M.C.; Fons, A.C.; Machado, I. Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a CDKN2A germline mutation carrier. World J. Gastrointest. Oncol. 2017, 9, 390–396. [Google Scholar] [CrossRef]
  30. Matsuzaka, S.; Karasaki, H.; Ono, Y.; Ogata, M.; Oikawa, K.; Tamakawa, S.; Chiba, S.; Muraki, M.; Yokochi, T.; Funakoshi, H.; et al. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas 2016, 45, 915–918. [Google Scholar] [CrossRef]
  31. Boecker, W.; Tiemann, K.; Boecker, J.; Toma, M.; Muders, M.H.; Loning, T.; Buchwalow, I.; Oldhafer, K.J.; Neumann, U.; Feyerabend, B.; et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: Evidence supporting the squamous metaplasia concept. Histochem. Cell Biol. 2020, 154, 97–105. [Google Scholar] [CrossRef] [PubMed]
  32. Na, Y.J.; Shim, K.N.; Cho, M.S.; Sung, S.H.; Jung, S.A.; Yoo, K.; Chung, K.W. Primary adenosquamous cell carcinoma of the pancreas: A case report with a review of the Korean literature. Korean J. Intern. Med. 2011, 26, 348–351. [Google Scholar] [CrossRef] [PubMed]
  33. Fang, Y.; Su, Z.; Xie, J.; Xue, R.; Ma, Q.; Li, Y.; Zhao, Y.; Song, Z.; Lu, X.; Li, H.; et al. Genomic signatures of pancreatic adenosquamous carcinoma (PASC). J. Pathol. 2017, 243, 155–159. [Google Scholar] [CrossRef] [PubMed]
  34. Marcus, R.; Maitra, A.; Roszik, J. Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. J. Pathol. 2017, 243, 271–272. [Google Scholar] [CrossRef] [Green Version]
  35. Madura, J.A.; Jarman, B.T.; Doherty, M.G.; Yum, M.N.; Howard, T.J. Adenosquamous carcinoma of the pancreas. Arch. Surg. 1999, 134, 599–603. [Google Scholar] [CrossRef] [Green Version]
  36. Altshuler, J.H.; Shaka, J.A. Squamous cell carcinoma of the stomach. Review of the literature and report of a case. Cancer 1966, 19, 831–838. [Google Scholar] [CrossRef] [PubMed]
  37. Brody, J.R.; Costantino, C.L.; Potoczek, M.; Cozzitorto, J.; McCue, P.; Yeo, C.J.; Hruban, R.H.; Witkiewicz, A.K. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod. Pathol. 2009, 22, 651–659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Liu, C.; Karam, R.; Zhou, Y.; Su, F.; Ji, Y.; Li, G.; Xu, G.; Lu, L.; Wang, C.; Song, M.; et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat. Med. 2014, 20, 596–598. [Google Scholar] [CrossRef] [Green Version]
  39. Witkiewicz, A.K.; McMillan, E.A.; Balaji, U.; Baek, G.; Lin, W.-C.; Mansour, J.; Mollaee, M.; Wagner, K.-U.; Koduru, P.; Yopp, A.; et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 2015, 6, 6744. [Google Scholar] [CrossRef]
  40. Xu, M.D.; Liu, S.L.; Feng, Y.Z.; Liu, Q.; Shen, M.; Zhi, Q.; Liu, Z.; Gu, D.M.; Yu, J.; Shou, L.M.; et al. Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. Oncotarget 2017, 8, 14620–14635. [Google Scholar] [CrossRef] [Green Version]
  41. Ma, H.; Song, B.; Guo, S.; Li, G.; Jin, G. Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing. Cancer Biomark. 2020, 27, 389–397. [Google Scholar] [CrossRef] [PubMed]
  42. Lenkiewicz, E.; Malasi, S.; Hogenson, T.L.; Flores, L.F.; Barham, W.; Phillips, W.J.; Roesler, A.S.; Chambers, K.R.; Rajbhandari, N.; Hayashi, A.; et al. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. Cancer Res. 2020, 80, 4324–4334. [Google Scholar] [CrossRef] [PubMed]
  43. Brunetti, O.; Aprile, G.; Marchetti, P.; Vasile, E.; Casadei Gardini, A.; Scartozzi, M.; Barni, S.; Delfanti, S.; De Vita, F.; Di Costanzo, F.; et al. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. Pancreas 2018, 47, 759–771. [Google Scholar] [CrossRef] [PubMed]
  44. Gill, A.J.; Klimstra, D.S.; Lam, A.K.; Washington, M.K. Tumours of the Pancreas. In Digestive System Tumours, Vol. 1. WHO Classification of Tumours Series, 5th ed.; WHO Classification of Tumours Editorial Board; World Health Organization: Lyon, France, 2019; pp. 296–372. [Google Scholar]
  45. Murakami, Y.; Yokoyama, T.; Yokoyama, Y.; Kanehiro, T.; Uemura, K.; Sasaki, M.; Morifuji, M.; Sueda, T. Adenosquamous carcinoma of the pancreas: Preoperative diagnosis and molecular alterations. J. Gastroenterol. 2003, 38, 1171–1175. [Google Scholar] [CrossRef] [PubMed]
  46. Basil, M.; Pudusseri, A.; Lowe, R. Weight Loss and Abdominal Pain Caused by Pancreatic Squamous Cell Carcinoma. Clin. Gastroenterol. Hepatol. 2017, 15, A41–A42. [Google Scholar] [CrossRef] [Green Version]
  47. Ben Kridis, W.; Khanfir, A.; Toumi, N.; Ben Amar, M.; Boudawara, T.; Frikha, M. Primary squamous cell carcinoma of the pancreas: A report of two cases and review of the literature. Intern. Med. 2015, 54, 1357–1359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Hsu, J.T.; Chen, H.M.; Wu, R.C.; Yeh, C.N.; Yeh, T.S.; Hwang, T.L.; Jan, Y.Y.; Chen, M.F. Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma. World J. Surg. Oncol. 2008, 6, 95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Wahab, A.; Gonzalez, J.J.; Devarkonda, V.; Saint-Phard, T.; Singh, T.; Adekolujo, O.S. Squamous cell carcinoma-A rare pancreatic exocrine malignancy. Cancer Biol. 2019, 20, 593–596. [Google Scholar] [CrossRef]
  50. Itani, K.M.; Karni, A.; Green, L. Squamous cell carcinoma of the pancreas. J. Gastrointest. Surg. 1999, 3, 512–515. [Google Scholar] [CrossRef]
  51. Horino, K.; Takamori, H.; Ikuta, Y.; Nakahara, O.; Chikamoto, A.; Ishiko, T.; Beppu, T.; Baba, H. Cutaneous metastases secondary to pancreatic cancer. World J. Gastrointest. Oncol. 2012, 4, 176–180. [Google Scholar] [CrossRef]
  52. Miyahara, M.; Hamanaka, Y.; Kawabata, A.; Sato, Y.; Tanaka, A.; Yamamoto, A.; Ueno, T.; Nishihara, K.; Suzuki, T. Cutaneous metastases from pancreatic cancer. Int. J. Pancreatol. 1996, 20, 127–130. [Google Scholar] [CrossRef] [PubMed]
  53. Salari, B.; Sheinbein, D.M.; Rosman, I.S.; Dehner, L.P. Metastatic pancreatic adenosquamous carcinoma to the scalp: A case report and review of the literature. J. Cutan. Pathol. 2020, 47, 263–268. [Google Scholar] [CrossRef] [PubMed]
  54. Yin, Q.; Wang, C.; Wu, Z.; Wang, M.; Cheng, K.; Zhao, X.; Yuan, F.; Tang, Y.; Miao, F. Adenosquamous carcinoma of the pancreas: Multidetector-row computed tomographic manifestations and tumor characteristics. J. Comput. Assist. Tomogr. 2013, 37, 125–133. [Google Scholar] [CrossRef] [PubMed]
  55. Brayko, C.M.; Doll, D.C. Squamous cell carcinoma of the pancreas associated with hypercalcemia. Gastroenterology 1982, 83, 1297–1299. [Google Scholar] [CrossRef]
  56. Inoue, T.; Nagao, S.; Tajima, H.; Okudaira, K.; Hashiguchi, K.; Miyazaki, J.; Matsuzaki, K.; Tsuzuki, Y.; Kawaguchi, A.; Itoh, K.; et al. Adenosquamous pancreatic cancer producing parathyroid hormone-related protein. J. Gastroenterol. 2004, 39, 176–180. [Google Scholar] [CrossRef]
  57. Kobayashi, N.; Higurashi, T.; Iida, H.; Mawatari, H.; Endo, H.; Nozaki, Y.; Tomimoto, A.; Yoneda, K.; Akiyama, T.; Fujita, K.; et al. Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J. Hepatobiliary Pancreat. Surg. 2008, 15, 531–535. [Google Scholar] [CrossRef]
  58. López-Tomassetti-Fernández, E.M.; Favre-Rizzo, J.; Delgado-Plasencia, L.; Hernández-Hernández, J.R. Hypercalcemia associated with adenosquamous pancreatic carcinoma: A reason to initiate palliative treatment. Rev. Esp. Enferm. Dig. 2013, 105, 425–428. [Google Scholar] [CrossRef] [Green Version]
  59. Ding, Y.; Zhou, J.; Sun, H.; He, D.; Zeng, M.; Rao, S. Contrast-enhanced multiphasic CT and MRI findings of adenosquamous carcinoma of the pancreas. Clin. Imaging 2013, 37, 1054–1060. [Google Scholar] [CrossRef]
  60. Feng, Y.F.; Chen, J.Y.; Chen, H.Y.; Wang, T.G.; Shi, D.; Lu, Y.F.; Pan, Y.; Shao, C.W.; Yu, R.S. 110 Patients with adenosquamous carcinomas of the pancreas (PASC): Imaging differentiation of small (≤3 cm) versus large (>3 cm) tumors. Abdom. Radiol. 2019, 44, 2466–2473. [Google Scholar] [CrossRef]
  61. Toshima, F.; Inoue, D.; Yoshida, K.; Yoneda, N.; Minami, T.; Kobayashi, S.; Ikdeda, H.; Matsui, O.; Gabata, T. Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. Abdom. Radiol. 2016, 41, 508–520. [Google Scholar] [CrossRef]
  62. Zhao, R.; Jia, Z.; Chen, X.; Ren, S.; Cui, W.; Zhao, D.L.; Wang, S.; Wang, J.; Li, T.; Zhu, Y.; et al. CT and MR imaging features of pancreatic adenosquamous carcinoma and their correlation with prognosis. Abdom. Radiol. 2019, 44, 2822–2834. [Google Scholar] [CrossRef] [PubMed]
  63. Schawkat, K.; Tsai, L.L.; Jaramillo-Cardoso, A.; Paez, S.N.; Moser, J.A.; Decicco, C.; Singer, T.; Glickman, J.; Brook, A.; Manning, M.A.; et al. Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. Clin. Imaging 2021, 73, 134–138. [Google Scholar] [CrossRef] [PubMed]
  64. Jiang, L.; Nie, H.; Zhu, L.; Xiu, Y.; Shi, H. Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. Clin. Nucl. Med. 2017, 42, 206–208. [Google Scholar] [CrossRef] [PubMed]
  65. Su, W.; Zhao, S.; Chen, Y.; Zuo, C.; Cui, B.; Wang, M.; Ren, F. (18)F-FDG PET/CT feature of pancreatic adenosquamous carcinoma with pathological correlation. Abdom. Radiol. 2020, 45, 743–749. [Google Scholar] [CrossRef]
  66. Hoshimoto, S.; Hoshi, N.; Hishinuma, S.; Shirakawa, H.; Tomikawa, M.; Ozawa, I.; Wakamatsu, S.; Hoshi, S.; Hirabayashi, K.; Ogata, Y. Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. Pancreatology 2017, 17, 788–794. [Google Scholar] [CrossRef]
  67. Taniwaki, S.; Hisaka, T.; Sakai, H.; Goto, Y.; Nomura, Y.; Kawahara, R.; Ishikawa, H.; Yasunaga, M.; Naito, Y.; Akiba, J.; et al. Sarcomatous Component in Pancreatic Adenosquamous Carcinoma: A Clinicopathological Series of 7 Cases. Anticancer Res. 2019, 39, 4575–4580. [Google Scholar] [CrossRef] [Green Version]
  68. Imaoka, H.; Shimizu, Y.; Mizuno, N.; Hara, K.; Hijioka, S.; Tajika, M.; Kondo, S.; Tanaka, T.; Ogura, T.; Obayashi, T.; et al. Clinical characteristics of adenosquamous carcinoma of the pancreas: A matched case-control study. Pancreas 2014, 43, 287–290. [Google Scholar] [CrossRef]
  69. Miura, K.; Kanazawa, A.; Shimizu, S.; Murata, A.; Kodai, S.; Nishii, T.; Sakurai, K.; Tachimori, A.; Tamamori, Y.; Kubo, N.; et al. [A Resected Case of Adenosquamous Carcinoma of Pancreas That Relapsed in Remnant Pancreas]. Gan Kagaku Ryoho 2018, 45, 524–526. [Google Scholar]
  70. Ito, T.; Sugiura, T.; Okamura, Y.; Yamamoto, Y.; Ashida, R.; Ohgi, K.; Sasaki, K.; Uesaka, K. Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas. Surg. Today 2019, 49, 809–819. [Google Scholar] [CrossRef]
  71. Smoot, R.L.; Zhang, L.; Sebo, T.J.; Que, F.G. Adenosquamous carcinoma of the pancreas: A single-institution experience comparing resection and palliative care. J. Am. Coll. Surg. 2008, 207, 368–370. [Google Scholar] [CrossRef]
  72. Hester, C.A.; Augustine, M.M.; Choti, M.A.; Mansour, J.C.; Minter, R.M.; Polanco, P.M.; Porembka, M.R.; Wang, S.C.; Yopp, A.C. Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. J. Surg. Oncol. 2018, 118, 21–30. [Google Scholar] [CrossRef] [PubMed]
  73. Katz, M.H.; Taylor, T.H.; Al-Refaie, W.B.; Hanna, M.H.; Imagawa, D.K.; Anton-Culver, H.; Zell, J.A. Adenosquamous versus adenocarcinoma of the pancreas: A population-based outcomes analysis. J. Gastrointest. Surg. 2011, 15, 165–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Hsu, J.T.; Yeh, C.N.; Chen, Y.R.; Chen, H.M.; Hwang, T.L.; Jan, Y.Y.; Chen, M.F. Adenosquamous carcinoma of the pancreas. Digestion 2005, 72, 104–108. [Google Scholar] [CrossRef] [PubMed]
  75. Okabayashi, T.; Hanazaki, K. Surgical outcome of adenosquamous carcinoma of the pancreas. World J. Gastroenterol. 2008, 14, 6765–6770. [Google Scholar] [CrossRef] [PubMed]
  76. Kawai, K.; Okamura, H.; Fujiwara, A.; Yoshii, K.; Sagara, Y. [A Case of Locally Advanced Adenosquamous Carcinoma of the Pancreas Accompanied by Hepatic Metastasis Treated by Resection of the Primary Lesion as Palliative Care]. Gan Kagaku Ryoho 2019, 46, 2201–2203. [Google Scholar]
  77. Aurilio, G.; Macarulla, T.; Ramos, J.F.; Fazio, N.; Nolè, F.; Iglesias, C. Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma. Tumori 2011, 97, 239–242. [Google Scholar] [CrossRef]
  78. Ikeda, A.; Okuno, T.; Miki, I.; Yokozaki, H.; Kutsumi, H.; Azuma, T. A case report: Pancreatic squamous cell carcinoma with effective response by S-1 therapy. Clin. J. Gastroenterol. 2014, 7, 79–83. [Google Scholar] [CrossRef]
  79. Kaneta, A.; Tsuchiya, T.; Saito, T.; Otani, S.; Ito, F.; Miura, J. [Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail]. Gan Kagaku Ryoho 2016, 43, 2347–2349. [Google Scholar]
  80. Tella, S.H.; Kommalapati, A.; Yadav, S.; Bergquist, J.R.; Truty, M.J.; Durgin, L.; Ma, W.W.; Cleary, S.P.; McWilliams, R.R.; Mahipal, A. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. Eur. J. Surg. Oncol. 2019, 45, 1700–1705. [Google Scholar] [CrossRef]
  81. De Souza, A.L.; Saif, M.W. Platinum-based therapy in adenosquamous pancreatic cancer: Experience at two institutions. JOP 2014, 15, 144–146. [Google Scholar] [CrossRef]
  82. Wild, A.T.; Dholakia, A.S.; Fan, K.Y.; Kumar, R.; Moningi, S.; Rosati, L.M.; Laheru, D.A.; Zheng, L.; De Jesus-Acosta, A.; Ellsworth, S.G.; et al. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J. Gastrointest. Oncol. 2015, 6, 115–125. [Google Scholar] [CrossRef] [PubMed]
  83. Connell, C.M.; Brais, R.; Whitaker, H.; Upponi, S.; Beh, I.; Risdall, J.; Corrie, P.; Janowitz, T.; Jodrell, D.I. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: A case report. BMC Cancer 2020, 20, 38. [Google Scholar] [CrossRef] [PubMed]
  84. Chidimatsu, H.; Matsui, H.; Tokumitsu, Y.; Matsukuma, S.; Shindo, Y.; Tomochika, S.; Yoshida, S.; Iida, M.; Suzuki, N.; Takeda, S.; et al. [A Case of Borderline Resectable Pancreatic Adenosquamous Carcinoma Achieving Pathological Complete Response]. Gan Kagaku Ryoho 2019, 46, 2425–2427. [Google Scholar]
  85. Sumiyoshi, H.; Matsushita, A.; Nakamura, Y.; Yamahatsu, K.; Katsuno, A.; Uchida, E. [Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy–A case report]. Gan Kagaku Ryoho 2014, 41, 669–672. [Google Scholar]
  86. Moslim, M.A.; Lefton, M.D.; Ross, E.A.; Mackrides, N.; Reddy, S.S. Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience. J. Surg. Res. 2021, 259, 350–356. [Google Scholar] [CrossRef]
  87. Tanigawa, M.; Naito, Y.; Akiba, J.; Kawahara, A.; Okabe, Y.; Ishida, Y.; Ishikawa, H.; Hisaka, T.; Fujita, F.; Yasunaga, M.; et al. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. Pathol. Res. Pract. 2018, 214, 2069–2074. [Google Scholar] [CrossRef]
  88. Herman, J.M.; Swartz, M.J.; Hsu, C.C.; Winter, J.; Pawlik, T.M.; Sugar, E.; Robinson, R.; Laheru, D.A.; Jaffee, E.; Hruban, R.H.; et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J. Clin. Oncol. 2008, 26, 3503–3510. [Google Scholar] [CrossRef]
  89. Fushimi, K.; Kusashio, K.; Yasutomi, J.; Matsumoto, M.; Suzuki, T.; Iida, A.; Imamura, N.; Harano, R.; Kosaki, R.; Togasaki, K.; et al. [Adenosquamous Carcinoma in the Remnant Pancreas after Pancreatoduodenectomy for Invasive Pancreas Cancer-A Resected Case with Five-Year Relapse-Free Survival]. Gan Kagaku Ryoho 2019, 46, 2198–2200. [Google Scholar]
  90. Matsubayashi, H.; Matsunaga, K.; Uesaka, K.; Kanemoto, H.; Ito, I.; Asakura, H.; Yagishita, A.; Ono, H. Pancreatic adenosquamous carcinoma with 7-year survival: A case report and literature review. J. Dig. Dis. 2013, 14, 207–210. [Google Scholar] [CrossRef]
  91. Komatsu, H.; Kashiwazaki, M.; Hasegawa, N.; Nishizawa, Y.; Nakatsuka, R.; Miyazaki, S.; Komori, T.; Motoori, M.; Yakushijin, T.; Fushimi, H.; et al. A Case of Adenosquamous Carcinoma of Pancreas Treated with Conversion Surgery after Systemic Chemotherapy. Gan Kagaku Ryoho 2019, 46, 546–548. [Google Scholar]
  92. Kudo, H.; Seyama, Y.; Kanomata, H.; Takahashi, M.; Chang, T.; Matsuoka, Y.; Machida, T.; Furumoto, Y.; Warabi, M.; Tanizawa, T.; et al. [A Case of Resection of Advanced Pancreatic Adenosquamous Carcinoma in which Multidisciplinary Treatment Was Effective]. Gan Kagaku Ryoho 2019, 46, 178–180. [Google Scholar]
  93. Mashiko, T.; Nakano, A.; Masuoka, Y.; Yamamoto, S.; Ozawa, S.; Nakagohri, T. [Radical Resection of a Locally Advanced Unresectable Pancreatic Adenosquamous Carcinoma after Treatment with Systemic Chemotherapy]. Gan Kagaku Ryoho 2020, 47, 1233–1235. [Google Scholar]
  94. Tsujie, M.; Hirao, M.; Koga, C.; Wakasugi, M.; Inoue, T.; Kato, K.; Okamoto, K.; Yoshikawa, Y.; Sueda, T.; Matsumura, T.; et al. A Case of Advanced Adenosquamous Carcinoma of Pancreas with Conversion Surgery after Chemoradiotherapy Followed by Systemic Chemotherapy. Gan Kagaku Ryoho 2020, 47, 2412–2414. [Google Scholar]
  95. Zhang, G.; Cheng, Z.Z.; Xu, G.H.; Jiang, X.; Wang, X.X.; Wang, Q.F. Primary squamous cell carcinoma of the pancreas with effective comprehensive treatment: A case report and literature review. Medicine 2018, 97, e12253. [Google Scholar] [CrossRef]
  96. Elias, A.; Chatzizacharias, N.A.; Xanthis, A.; Corrie, P.; Davies, S.; Brais, R.J.; Jamieson, N.V.; Praseedom, R.K.; Huguet, E.; Harper, S.J.; et al. Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: A case report. Medicine 2015, 94, e499. [Google Scholar] [CrossRef] [PubMed]
  97. Qin, W.X.; Wu, Y.; Liu, J.; Qin, B.D.; Liu, K.; Jiao, X.D.; Wang, Z.; Chen, W.S.; Zang, Y.S. Primary squamous cell carcinoma of pancreas: A population-based study. Gland Surg. 2021, 10, 1029–1037. [Google Scholar] [CrossRef] [PubMed]
  98. Pokrzywa, C.J.; Abbott, D.E.; Matkowskyj, K.A.; Ronnekleiv-Kelly, S.M.; Winslow, E.R.; Weber, S.M.; Fisher, A.V. Natural History and Treatment Trends in Pancreatic Cancer Subtypes. J. Gastrointest. Surg. 2019, 23, 768–778. [Google Scholar] [CrossRef]
  99. Brunetti, O.; Luchini, C.; Argentiero, A.; Tommasi, S.; Mangia, A.; Aprile, G.; Marchetti, P.; Vasile, E.; Casadei Gardini, A.; Scartozzi, M.; et al. The Italian Rare Pancreatic Exocrine Cancer Initiative. Tumori 2019, 105, 353–358. [Google Scholar] [CrossRef] [Green Version]
  100. Mulkeen, A.L.; Yoo, P.S.; Cha, C. Less common neoplasms of the pancreas. World J. Gastroenterol. 2006, 12, 3180–3185. [Google Scholar] [CrossRef]
Table
Table 2. The comparison of outcomes between PSC and PDAC from published studies.
Table 2. The comparison of outcomes between PSC and PDAC from published studies.
ReferencesYear of StudyNumber of PatientsMedian Survival
(Months)		Postoperative Median Survival (Months)One-Year Survival Rate (%)
PDACPSCPDACPSCp ValuePDACPSCp ValuePDACPSC
Boyd et al. [5]1988–200745,693415540.081612<0.000124.721.2
Imaoka et al. [68]2001–2011562815.78.30.026NANANA63.538.7
Simone et al. [6]2001–2011230720.48.20.23NANANA0 (three-year survival rate)19 (three-year survival rate)
Katz et al. [73]2000–200714,74695Not mentioned40.41NA12NANANA
Voong et al. [4,88]1993–2005;
1986–2007		90838NANANA17.910.9NANANA
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Xiong, Q.; Zhang, Z.; Xu, Y.; Zhu, Q. Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer. J. Clin. Med. 2022, 11, 7401. https://doi.org/10.3390/jcm11247401

AMA Style

Xiong Q, Zhang Z, Xu Y, Zhu Q. Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer. Journal of Clinical Medicine. 2022; 11(24):7401. https://doi.org/10.3390/jcm11247401

Chicago/Turabian Style

Xiong, Qunli, Zhiwei Zhang, Yongfeng Xu, and Qing Zhu. 2022. "Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer" Journal of Clinical Medicine 11, no. 24: 7401. https://doi.org/10.3390/jcm11247401

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop